Deep Dive: Access and Commercialisation

Digital
Time to fix pharma’s outdated business model

Time to fix pharma’s outdated business model

The disconnect between payers and pharma companies is just one symptom of pharma’s outdated business model, according to Janssen’s company group chairman EMEA, Kris Sterkens.

Digital
Bringing gene therapies to market

Bringing gene therapies to market

Doug Danison, vice-president, head of access, value and evidence strategy at bluebird bio, a gene therapy company, looks at the obstacles, opportunities and required change in thinking need

Digital
NHS England gets commercial

NHS England gets commercial

NHS England is no longer the new kid on the block, taking up its role in 2013. In 2019, NHS England is a commercially savvy organisation when it comes to all things to do with medicines.

Digital
Under the skin of innovation

Under the skin of innovation

LEO’s Innovation Lab is working at arm’s length from the main company to encourage original thinking and develop cutting edge tech for dermatology.

Digital
How digital could transform stakeholder engagement

How digital could transform stakeholder engagement

Digital may be upending every aspect of the pharma industry, but many would assume that engagement activities like advisory boards, working groups and medical education will remain a bastio

Digital
The future of R&D innovation

The future of R&D innovation

Alexander Gray and Mike Rea from IDEA Pharma explain why the current pharma R&D model is broken, and how it’s hindering commercialisation for companies across the industry